Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159081 | 0.90 | TAAR1 (0.37) | TAAR1TSHRSMYD2HTTCYP3A4 | |
| SCHEMBL19714856 | 0.86 | SCN9A (0.37) | TAAR1TSHRSMYD2HTTCYP3A4 | |
| SCHEMBL19714829 | 0.85 | TAAR1 (0.34) | TAAR1TSHRSMYD2LMNAPOLB | |
| SCHEMBL19714898 | 0.85 | SMYD2 (0.37) | TAAR1TSHRSMYD2HTTCYP3A4 | |
| SCHEMBL19714910 | 0.85 | TAAR1 (0.34) | TAAR1TSHRSMYD2HTTCYP3A4 | |
| SCHEMBL19714873 | 0.83 | SMYD2 (0.36) | SMYD2HTTCYP3A4SMN1; SMN2 | |
| SCHEMBL18170205 | 0.80 | NT5E (0.39) | TAAR1TSHRSMYD2LMNAHRH4 | |
| SCHEMBL19714839 | 0.79 | SMYD2 (0.38) | TSHRSMYD2HTTCYP3A4SMN1; SMN2 | |
| SCHEMBL10236926 | 0.78 | SMYD2 (0.39) | SMYD2HTTCYP3A4SMN1; SMN2 | |
| SCHEMBL25263191 | 0.78 | SMYD2 (0.37) | TAAR1SMYD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | TAAR1 1488/4885TSHR 2071/4885SMYD2 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.